Renin–Angiotensin System

Overview

The renin–angiotensin system (RAS), also referred to as the renin–angiotensin–aldosterone system (RAAS), is a critical endocrine pathway that maintains cardiovascular homeostasis. It functions through a cascade of enzymatic reactions that ultimately produce angiotensin II, a potent vasoconstrictor, and stimulates the release of aldosterone, a mineralocorticoid hormone responsible for sodium and water retention[1]

First described in the early 20th century, the RAS has evolved from a renal-centric model to a complex network involving tissue-specific pathways that influence inflammation, fibrosis, and cellular metabolism across multiple organs[2]

Biochemical Pathway

The classical RAS pathway initiates in the juxtaglomerular apparatus of the kidney and proceeds through three primary enzymatic steps:

1. Renin release: Secreted by juxtaglomerular (JG) cells in response to decreased renal perfusion, sympathetic stimulation, or reduced NaCl delivery to the macula densa[3]
   Leyssac PP. The juxtaglomerular apparatus: structure and function. *Acta Physiol Scand Suppl*. 1983;519:1-79.
   .
2. Angiotensinogen cleavage: Renin converts hepatic angiotensinogen into angiotensin I (octadecapeptide).
3. ACE-mediated conversion: Angiotensin-converting enzyme (ACE), primarily located in pulmonary endothelium, removes two C-terminal amino acids to form angiotensin II (octapeptide)[4]
   Carretero OA, Oparil S. Essential hypertension. *Lancet*. 2000;355(9219):1440-1447.
   .

Renin: The Rate-Limiting Enzyme

Renin is an aspartyl protease (EC 3.4.23.15) with an optimal pH of 6.0–7.5. Its secretion is tightly regulated by three primary mechanisms:

• Renal baroreceptors: Detect decreases in afferent arteriolar pressure
• Macula densa signaling: Responds to reduced NaCl concentration in the distal tubule
• Sympathetic nervous system: β1-adrenergic stimulation enhances JG cell renin release[5]
  Imig JD. The renal sympathetic nervous system in hypertension. *Clin Exp Pharmacol Physiol*. 2008;35(1):8-12.

Plasma renin activity (PRA) serves as a clinical biomarker for volume status and is utilized in diagnosing primary hyperaldosteronism versus secondary hypertension.

Angiotensin I & II

Angiotensin I

A biologically inactive decapeptide that circulates with a half-life of approximately 5–15 minutes. While traditionally considered an inactive intermediate, recent evidence suggests minor vasodilatory properties via endothelial nitric oxide pathways[6]

Angiotensin II

Angiotensin II (Ang II) is the primary effector peptide, exerting effects through two main G-protein coupled receptors:

• AT1 receptor: Mediates vasoconstriction, aldosterone secretion, sympathetic activation, sodium retention, cellular hypertrophy, inflammation, and oxidative stress[7]
  Chappell MC, et al. AT(1) and AT(2) receptor signaling: the classic renin-angiotensin system. *Adv Pharmacol*. 2010;58:121-144.
• AT2 receptor: Generally opposes AT1 signaling, promoting vasodilation, apoptosis, anti-fibrotic effects, and cellular differentiation. Expression increases during development and tissue injury[8]
  Fuchs E, et al. The AT2 receptor and its role in cardiovascular homeostasis. *J Hypertens*. 2007;25(7):1333-1343.

Aldosterone & Target Organs

Ang II stimulates zona glomerulosa cells of the adrenal cortex to synthesize and release aldosterone. Aldosterone acts on principal cells of the renal collecting duct, upregulating epithelial sodium channels (ENaC) and Na⁺/K⁺-ATPase, promoting sodium reabsorption and potassium excretion[9]

Beyond the kidneys, RAS components exhibit tissue-specific expression in the heart, brain, vasculature, and reproductive organs, where they modulate local inflammation, remodeling, and neuroprotection independent of circulating hormone levels.

Clinical Significance

Dysregulation of the RAS is implicated in numerous pathological states:

• Hypertension: Chronic AT1 activation leads to vascular remodeling and increased peripheral resistance
• Heart Failure: Compensatory RAS activation initially maintains perfusion but progressively promotes ventricular hypertrophy and fibrosis
• Diabetic Nephropathy: Glomerular hyperfiltration and mesangial expansion driven by intrarenal angiotensin II
• Acute Kidney Injury: Ischemic stress triggers maladaptive RAS activation, exacerbating tubular necrosis

Pharmacological Inhibitors

Targeting the RAS represents one of the most successful strategies in modern cardiology and nephrology:

Clinical trials such as HOPE, VAL-HeFT, and RASSAAL have demonstrated consistent mortality and morbidity benefits, though combination ACEi/ARB therapy is generally avoided due to increased risk of hyperkalemia and acute kidney injury without additional benefit[10]